SLC6A5 Gene as Potential Drug Target Or Biomarker for Various Diseases

Target Name: SLC6A5

NCBI ID: G9152

SLC6A5

SLC6A5 Gene as Potential Drug Target Or Biomarker for Various Diseases

SLC6A5 (GlyT2) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The gene is located on the shortest staining ome in the human genome, making it a good candidate for a gene that has a small number of functionally independent variants.

SLC6A5 is a gene that encodes a protein known as GlyT2, which is a transmembrane protein that is involved in various cellular processes, including cell signaling, neurotransmitter release, and intracellular signaling. GlyT2 is a protein that is expressed in many different tissues and cells in the body, including the brain, heart, and pancreas.

One of the key functions of GlyT2 is its role in intracellular signaling. The protein is involved in the regulation of various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and survival. GlyT2 is also involved in the regulation of the NF-kappa-B pathway, which is involved in inflammation and immune responses.

In addition to its role in intracellular signaling, GlyT2 is also involved in the regulation of various extracellular events, including cell adhesion, migration, and invasion. The protein is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues and organs. GlyT2 is also involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed.

GlyT2 has also been shown to be involved in the regulation of various signaling pathways that are involved in cancer progression. The protein has been shown to be involved in the regulation of the PI3K/AKT signaling pathway, which is involved in the regulation of cell growth and survival. GlyT2 has also been shown to be involved in the regulation of the NF-kappa-B pathway, which is involved in inflammation and immune responses.

In addition to its involvement in intracellular and extracellular signaling, GlyT2 has also been shown to be involved in the regulation of various cellular processes that are important for normal development and function. The protein is involved in the regulation of cell cycle progression, which is the process by which cells grow and divide. GlyT2 is also involved in the regulation of DNA replication, which is an important step in the regulation of cell growth and development.

GlyT2 has also been shown to be involved in the regulation of various signaling pathways that are involved in neurodegenerative diseases. The protein has been shown to be involved in the regulation of the TGF-β pathway, which is involved in cell growth, differentiation, and survival. GlyT2 has also been shown to be involved in the regulation of the NF-kappa-B pathway, which is involved in inflammation and immune responses.

In addition to its involvement in neurodegenerative diseases, GlyT2 has also been shown to be involved in the regulation of various signaling pathways that are involved in autoimmune disorders. The protein has been shown to be involved in the regulation of the TGF-β pathway, which is involved in cell growth, differentiation, and survival. GlyT2 has also been shown to be involved in the regulation of the NF-kappa-B pathway, which is involved in inflammation and immune responses.

GlyT2 has also been shown to be involved in the regulation of various signaling pathways that are involved in cancer. The protein has been shown to be involved in the regulation of the PI3K/AKT signaling pathway, which is involved in cell growth and survival. has also been shown to be involved in the regulation of the NF-kappa-B pathway, which is involved in inflammation and immune responses.

GlyT2 is also a good candidate for a biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The protein is expressed in many different tissues and cells in the body, including the brain, heart, and pancreas. This makes it

Protein Name: Solute Carrier Family 6 Member 5

Functions: Sodium- and chloride-dependent glycine transporter (PubMed:9845349, PubMed:10381548, PubMed:10606742, PubMed:31370103, PubMed:16751771). Terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals (PubMed:9845349). May be responsible for the termination of neurotransmission at strychnine-sensitive glycinergic synapses (PubMed:9845349)

The "SLC6A5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets